Back to UBS Group AG UBS Group AG

SYRESYRE
11 quarters

Position history for UBS Group AGUBS Group AG's holdings in SPYRE THERAPEUTICS INC

UBS Group AG holds 843,071 shares of SYRE (SPYRE THERAPEUTICS INC), worth $74.8M as of 2026-Q2. The position was increased (+25.6% shares). SYRE represents 0.0% of UBS Group AG's portfolio.

Current Value

$74.8M

Current Shares

843,071

Total Value Change

+$74.8M

Total Shares Change

+839,345

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Increased
843,071
+25.6%
$74.8M0.0%$88.78
36
2026-Q1
Decreased
671,235
-1.4%
$33.9M0.0%$40.07
0
2025-Q4
Increased
680,566
+76.5%
$22.3M0.0%$31.88
43
2025-Q3
Decreased
385,589
-16.7%
$6.5M0.0%$16.36
0
2025-Q2
Decreased
462,863
-16.2%
$6.9M0.0%$15.22
0
2025-Q1
Increased
552,243
+40.8%
$8.9M0.0%$17.94
37
2024-Q4
Increased
392,197
+578.1%
$9.1M0.0%$22.54
45
2024-Q3
Increased
57,838
+30.0%
$1.7M0.0%$28.49
32
2024-Q2
Increased
44,504
+1611.0%
$1M0.0%$23.51
40
2024-Q1
Decreased
2,601
-30.2%
$98,6560.0%$37.93
0
2023-Q4
New
3,726
-
$80,1840.0%$21.52
33

Other major holders of SYRE: FMR LLC, BlackRock, Inc., RTW INVESTMENTS, LP

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used